Skip to main content

New technologies for diabetes treatment

Guest Editors:
Clara Mosquera-Lopez, PhD, Artificial Intelligence for Medical Systems (AIMS) Lab, Department of Biomedical Engineering, Oregon Health & Science University, United States
Benjamin J. Wheeler, MB ChB(Otago) DCH PhD CCE FRACP, Department of Women’s & Children’s Health, Te Tari Hauora Wāhine me te Tamariki, Dunedin School of Medicine, University of Otago, New Zealand

BMC Endocrine Disorders called for submissions to our Collection on New technologies for diabetes treatment.

This Collection aimed to shed light on cutting-edge advancements in the field of diabetes management and treatment, with a strong emphasis on their potential to impact the lives of individuals living with diabetes. Diabetes, a chronic medical condition characterized by elevated blood glucose levels, affects millions of people worldwide. Its growing prevalence is a major global health concern, closely linked to obesity, lifestyle, and genetic factors.


New Content ItemThis Collection supports and amplifies research related to SDG 3: Good Health and Well-being.

Meet the Guest Editors

Back to top

Clara Mosquera-Lopez, PhD, Artificial Intelligence for Medical Systems (AIMS) Lab, Department of Biomedical Engineering, Oregon Health & Science University, United States

Dr Clara Mosquera-Lopez is currently an Assistant Professor and a member of the Artificial Intelligence for Medical Systems (AIMS) Laboratory in the Department of Biomedical Engineering (BME) at the School of Medicine, Oregon Health & Science University (OHSU). Dr Mosquera-Lopez's research interests lie within the general field of Computational Biology. Her current research focuses on data-driven modeling for developing and translating smart biosensors, AI-based decision support systems, and AI-augmented drug delivery systems with a focus on the management of type 1 diabetes. Before joining the AIMS Lab in the BME Department at OHSU, Dr Mosquera-Lopez served as a Senior Imaging Scientist at Intel Corporation. She holds a PhD in Electrical Engineering from the University of Texas at San Antonio.

Benjamin J. Wheeler, MB ChB(Otago) DCH PhD CCE FRACP, Department of Women’s & Children’s Health, Te Tari Hauora Wāhine me te Tamariki, Dunedin School of Medicine, University of Otago, New Zealand

Professor Ben Wheeler is a Pediatric Endocrinologist working for Health New Zealand - Southern Region. He is also Head of Child Health at the Dunedin School of Medicine, University of Otago. He has a strong clinical and research focus on access to and use of new technologies for children, youth, and adults affected by diabetes, as well as other factors that impact on glycemic control and diabetes burden. He has led and been involved in numerous clinical trials in this area.

About the Collection

BMC Endocrine Disorders is pleased to publish this Collection focusing on New technologies for diabetes treatment. This Collection aimed to shed light on cutting-edge advancements in the field of diabetes management and treatment, with a strong emphasis on their potential to impact the lives of individuals living with diabetes.

Diabetes, a chronic medical condition characterized by elevated blood glucose levels, affects millions of people worldwide. Its growing prevalence is a major global health concern, closely linked to obesity, lifestyle, and genetic factors. The urgency to find effective treatments and improve the quality of life for those living with diabetes cannot be overstated.

Innovations such as continuous glucose monitoring systems, automated insulin delivery systems, telemedicine, and personalized digital health tools have the potential to revolutionize diabetes management.

We welcomed submissions on a range of topics related to new technologies, including but not limited to:

  • New technologies empowering patients through real-time monitoring and data-driven insights
  • Advanced technologies enabling early detection and prediction of blood glucose fluctuations
  • Technology advancements allowing accessibility and affordability
  • Advances in personalized diabetes management using artificial intelligence
  • Developments in automated insulin delivery
  • Advances in decision support tools

Addressing diabetes aligns with Sustainable Development Goal 3: Good Health and Well-being. By fostering research in new technologies for diabetes treatment, we contribute to the global effort to reduce premature mortality from non-communicable diseases and ensure universal health coverage.

Image credit: natali_mis / stock.adobe.com

  1. Multiple clinician adjustable parameters impact upon glycemia in people with type 1 diabetes (T1D) using Medtronic Mini Med 780G (MM780G) AHCL. These include glucose targets, carbohydrate ratios (CR), and acti...

    Authors: Shekhar Sehgal, Martin De Bock, Benyamin Grosman, Jonathan Williman, Natalie Kurtz, Vanessa Guzman, Andrea Benedetti, Anirban Roy, Kamuran Turksoy, Magaly Juarez, Shirley Jones, Carla Frewen, Antony Watson, Barry Taylor and Benjamin J. Wheeler
    Citation: BMC Endocrine Disorders 2024 24:167
    Content type: Research Published on:

  2. Use of Continuous Subcutaneous Insulin Infusion (CSII) has been shown to improve glycemic outcomes in Type 1 Diabetes (T1D), but high costs limit accessibility. To address this issue, an inter-operable, open-s...

    Authors: Matthew Payne, Francis Pooke, Tom M. Wilkinson, Lui Holder-Pearson, Bronté Chamberlain, Martin de Bock and J. Geoffrey Chase
    Citation: BMC Endocrine Disorders 2024 24:134
    Content type: Research Published on:

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select New technologies for diabetes treatment from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.